Trastuzumab (TZM) is a humanized monoclonal antibody used as a drug to target the extracellular domain of human epidermal growth factor receptor 2 (HER2) and has shown good therapy efficacy on the majority of patients with HER2-positive breast cancer [1]. This evidence concerns the gene ERBB2 and breast carcinoma.